Successful treatment with immunosuppression, anticoagulation and vasodilator therapy of pulmonary hypertension in SLE associated with secondary antiphospholipid syndrome.
Severe pulmonary hypertension (PHT) occurring in patients with systemic lupus erythematosus (SLE) is uncommon. Different modalities have been tried in the treatment for this condition but have not been effective because of progressive increase of pulmonary resistance over time. Our patient with SLE and PHT with antiphospholipid syndrome (APS), a condition which has previously never been described, responded rapidly to combination treatment with immunosuppression, anticoagulation and vasodilator therapy.
Tam
L S
LS
Department of Medicine and Therapeutics, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong.
Li
E K
EK
D000328:Adult; D000925:Anticoagulants / Q000627:therapeutic use*; D016736:Antiphospholipid Syndrome / Q000188:drug therapy* / Q000209:etiology; D003520:Cyclophosphamide / Q000627:therapeutic use; D004110:Diltiazem / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D006976:Hypertension, Pulmonary / Q000188:drug therapy* / Q000209:etiology; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D008180:Lupus Erythematosus, Systemic / Q000150:complications / Q000188:drug therapy*; D011241:Prednisone / Q000627:therapeutic use; D014665:Vasodilator Agents / Q000627:therapeutic use*; D014859:Warfarin / Q000627:therapeutic use*
D000925:Anticoagulants; D007166:Immunosuppressive Agents; D014665:Vasodilator Agents; D014859:Warfarin; D003520:Cyclophosphamide; D004110:Diltiazem; D011241:Prednisone